

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on January 10, 2001.

Karen LePari

Karen LePari



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JAN 18 2001

TECH CENTER 1600/2900

In the application of:

Alessandro SETTE, et al.

Serial No.: 09/017,743

Filing Date: February 3, 1998

For: HLA BINDING PEPTIDES AND THEIR
USES

Examiner: M. DiBrino

Group Art Unit: 1644

TRANSMITTAL

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed please find the following:

1. Blanket U.S. Revocation Power of Attorney.
2. Return postcard.

The Assistant Commissioner is hereby authorized to charge any fees under
37 C.F.R. §§ 1.16, 1.17, and 1.21 that may be required by this transmittal, or to credit any
overpayment, to **Deposit Account No. 03-1952**.

Respectfully submitted,


Dated: January 10, 2001

By:


Kawai Lau
Registration No. 44,461 for

Kate H. Murashige
Registration No. 29,959

Morrison & Foerster LLP
3811 Valley Centre Drive, Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**REVOCATION OF PRIOR POWER OF ATTORNEY AND POWER OF ATTORNEY
AND PROSECUTION BY ASSIGNEE UNDER 37 C.F.R. § 3.71**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Epimmune, Inc., the assignee of the entire right, title and interest in these pending patent applications, issued patents and abandoned applications (attached as Appendices "A", "B", and "C" respectively), hereby revokes all Powers of Attorney previously granted relating to these applications and appoints as its attorneys or agents, with full power of substitution, association, and revocation, to prosecute this application and to transact all business in the United States Patent and Trademark Office connected herewith:

Laurie A. Axford (Reg No. 35,053)	Sanjay S. Bagade (Reg No. 42,280)
Joseph Barrera (Reg No. 44,522)	Erwin J. Basinski (Reg No. 34,773)
Shantanu Basu (Reg No. 43,318)	Richard R. Batt (Reg No. 43,485)
Frank P. Becking (Reg No. 42,309)	Vincent J. Belusko (Reg No. 30,820)
Kimberly A. Bolin (Reg No. 44,546)	Timothy J. Bortree (Reg No. 43,506)
Barry E. Bretschneider (Reg No. 28,055)	Tyler S. Brown (Reg No. 36,465)
Nicholas Buffinger (Reg No. 39,124)	Jingming Cai (Reg No. P-44,579)
Mark R. Carter (Reg No. 39,131)	Robert K. Cerpa (Reg No. 39,933)
Peng Chen (Reg No. 43,543)	Thomas Chuang (Reg No. P-44,616)
Thomas E. Ciotti (Reg No. 21,013)	Matthew M. D'Amore (Reg No. 42,457)
Raj S. Davé (Reg No. 42,465)	Stephen C. Durant (Reg No. 31,506)
Carolyn A. Favorito (Reg No. 39,183)	David L. Fehrman (Reg No. 28,600)
Hector Gallegos (Reg No. 40,614)	Debra J. Glaister (Reg No. 33,888)
Kenneth R. Glick (Reg No. 28,612)	Charles D. Holland (Reg No. 35,196)
Peter Hsieh (Reg No. P-44,780)	Madeline I. Johnston (Reg No. 36,174)
Richard D. Jordan (Reg No. 33,519)	Ararat Kapouytian (Reg No. 40,044)
Catherine J. Kara (Reg No. 41,106)	Richard C. Kim (Reg No. 40,046)
Kawai Lau (Reg No. 44,461)	Rimas T. Lukas (Reg No. 46,451)
Lisa E. Marks (Reg No. 44,901)	Gladys H. Monroy (Reg No. 32,430)
Philip A. Morin (Reg No. P-45,926)	Kate H. Murashige (Reg No. 29,959)
Martin M. Noonan (Reg No. 44,264)	Catherine M. Polizzi (Reg No. 40,130)
William C. Revelos (Reg No. 42,101)	Paul J. Riley (Reg No. 38,596)
Robert Saltzberg (Reg No. 36,910)	Debra A. Shetka (Reg No. 33,309)
Terri Shieh-Newton (Reg No. P-47,081)	Rebecca Shortle (Reg No. P47,083)

Kevin R. Spivak (Reg No. 43,148)
E. Thomas Wheelock (Reg No. 28,825)
Thomas G. Wiseman (Reg No. 35,046)
David T. Yang (Reg No. 44,415)
George C. Yu (Reg No. 44,418)

Stanley H. Thompson (Reg No. 45,160)
Todd W. Wight (Reg No. 45,218)
Frank Wu (Reg No. 41,386)
Peter J. Yim (Reg No. 44,417)
Karen R. Zachow (Reg No. P-46,332)

all of Morrison & Foerster LLP, 3811 Valley Centre Drive, Suite 500, San Diego, California 92130, telephone: (858) 720-5100, said appointment to be to the exclusion of the inventors and their attorneys in accordance with the provisions of 37 C.F.R. § 3.71 provided that if any one of said attorneys or agents ceases being affiliated with the law firm of Morrison & Foerster as partner, employee or of counsel, such attorney's or agent's appointment as attorney or agent and all powers derived therefrom shall terminate on the date such attorney or agent ceases being so affiliated.

Also, please recognize as Associate Attorney:

Timothy J. Lithgow, M.D., J.D. (Reg. No. 36,856)

Director Intellectual Property, EPIMMUNE, INC., 5820 Nancy Ridge Drive, San Diego, California 92121, telephone: (858) 860-2514.


Please direct all communications relative to this application to:

Kate H. Murashige
Morrison & Foerster LLP
3811 Valley Centre Drive, Suite 500
San Diego, CA 92130

Please direct all telephone communications to Kate H. Murashige at (858) 720-5112.

Epimmune, Inc.

Dated: December 11, 2000



Name: Timothy J. Lithgow, Esq.
Title: Director, Intellectual Property
Address: Epimmune, Inc.
5820 Nancy Ridge Drive
San Diego, CA 92121

APPENDIX "A"
(Pending Applications)

In the Applications of:

1. Serial No. 09/346,105, Filed June 30, 1999, Title: CONSISTENT IMMUNE RESPONSES IN DIVERSE GENETIC POPULATIONS;
2. Serial No. 08/347,610, Filed December 1, 1994, Title: HLA BINDING PEPTIDES AND THEIR USES;
3. Serial No. 08/821,739, Filed March 20, 1997, Title: HLA BINDING PEPTIDES AND THEIR USES;
4. Serial No. 09/017,524, Filed February 3, 1998, Title: HLA-a2 BINDING PEPTIDES AND THEIR USES;
5. Serial No. 08/205,713, Filed March 4, 1994, Title: HLA-A2.1 BINDING PEPTIDES AND THEIR USES;
6. Serial No. 08/349,177, Filed December 2, 1994, Title: HLA-A2 BINDING PEPTIDES AND THEIR USES;
7. Serial No. 08/454,033, Filed May 26, 1995, Title: HLA-A2 BINDING PEPTIDES AND THEIR USES;
8. Serial No. 09/017,735, Filed February 3, 1998, Title: HLA-A2 BINDING PEPTIDES AND THEIR USES;
9. Serial No. 08/344,824, Filed November 23, 1994, Title: HLA BINDING PEPTIDES AND THEIR USES;
10. Serial No. 08/452,843, Filed May 30, 1995, Title: HLA BINDING PEPTIDES AND THEIR USES;
11. Serial No. 09/017,743, Filed February 3, 1998, Title: HLA BINDING PEPTIDES AND THEIR USES;
12. Serial No. 09/491,678, Filed January 26, 2000, Title: IDENTIFICATION OF BROADLY REACTIVE HLA RESTRICTED T CELL EPITOPES A 1 SUPER MOTIF;
13. Serial No. 09/491,676, Filed January 26, 2000, Title: IDENTIFICATION OF BROADLY REACTIVE HLA RESTRICTED T CELL EPITOPES A 24 SUPER MOTIF;

14. Serial No. 09/492,883, Filed January 26, 2000, Title: IDENTIFICATION OF BROADLY REACTIVE HLA RESTRICTED T CELL EPITOPES B 27 SUPER MOTIF;
15. Serial No. 09/491,372, Filed January 26, 2000, Title: IDENTIFICATION OF BROADLY REACTIVE HLA RESTRICTED T CELL EPITOPES B 58 SUPER MOTIF; and
16. Serial No. 09/491,682, Filed January 26, 2000, Title: IDENTIFICATION OF BROADLY REACTIVE HLA RESTRICTED T CELL EPITOPES B 62 SUPER MOTIF.

APPENDIX "B"
(Issued Patents)

Issued Patents:

1. Patent No. 5,662,907, Issued September 2, 1997, Title: INDUCTION OF ANTI-TUMOR CYTOTOXIC T LYMPHOCYTES IN HUMANS USING SYNTHETIC PEPTIDE EPITOPE.

APPENDIX "C"
(Abandoned and/or Converted Applications)

In the Applications of:

1. Serial No. 07/926,666, Filed August 7, 1992, Title: HLA-A2.1 BINDING PEPTIDES AND THEIR USES (Abandoned);
2. Serial No. 08/027,746, Filed March 5, 1993, Title: HLA-A2.1 BINDING PEPTIDES AND THEIR USES (Abandoned);
3. Serial No. 08/103,396, Filed August 6, 1993, Title: HLA-A2.1 BINDING PEPTIDES AND THEIR USES (Abandoned);
4. Serial No. 09/116,061, Filed July 15, 1998, Title: HLA BINDING PEPTIDES AND THEIR USES (Abandoned);
5. Serial No. 08/451,913, Filed May 26, 1995, Title: HLA BINDING PEPTIDES AND THEIR USES (Abandoned);
6. Serial No. 08/589,107, Filed January 23, 1996, Title: HLA BINDING PEPTIDES AND THEIR USES (Abandoned);
7. Serial No. 08/758,409, Filed November 27, 1996, Title: HLA BINDING PEPTIDES AND THEIR USES (Abandoned);
8. Serial No. 08/027,146, Filed March 5, 1993, Title: HLA-A2.1 BINDING PEPTIDES AND THEIR USES (Abandoned);
9. Serial No. 08/073,205, Filed June 4, 1993, Title: HLA-A2.1 BINDING PEPTIDES AND THEIR USES (Abandoned);
10. Serial No. 08/159,184, Filed November 29, 1993, Title: HLA-A2.1 BINDING PEPTIDES AND THEIR USES (Abandoned);
11. Serial No. 09/116,424, Filed July 15, 1998, Title: HLA-A2.1 BINDING PEPTIDES AND THEIR USES (Abandoned);
12. Serial No. 08/589,108, Filed January 23, 1996, Title: HLA-A2.1 BINDING PEPTIDES AND THEIR USES (Abandoned);
13. Serial No. 08/822,382, Filed March 30, 1997, Title: HLA-A2.1 BINDING PEPTIDES AND THEIR USES (Abandoned);

14. Serial No. 08/783,622, Filed November 27, 1996, Title: HLA-A2.1 BINDING PEPTIDES AND THEIR USES (Abandoned);
15. Serial No. 08/278,634, Filed July 21, 1994, Title: APPLICATION RE NOVEL ANTIGEN RECOGNITION OF P 2 PEPTIDES (Abandoned);
16. Serial No. 09/115,400, Filed July 14, 1998, Title: HLA-A2.1 BINDING PEPTIDES AND THEIR USES (Abandoned);
17. Serial No. 08/590,298, Filed January 23, 1996, Title: HLA-A2.1 BINDING PEPTIDES AND THEIR USES (Abandoned);
18. Serial No. 08/753,615, Filed November 27, 1996, Title: HLA-A2.1 BINDING PEPTIDES AND THEIR USES (Abandoned);
19. Serial No. 08/815,369, Filed March 10, 1997, Title: PEPTIDES WITH INCREASED BINDING AFFINITY FOR HLA MOLECULES (Abandoned);
20. Serial No. 60/013,833, Filed March 21, 1996, Title: HLA-A2.1 BINDING PEPTIDES AND THEIR USES (Converted);
21. Serial No. 60/013,980, Filed March 21, 1996, Title: HLA BINDING PEPTIDES AND THEIR USES (Converted);
22. Serial No. 60/013,113, Filed March 11, 1996, Title: PEPTIDES WITH INCREASED BINDING AFFINITY FOR HLA MOLECULES (Converted); and
23. Serial No. 60/117,486, Title: HIGH THROUGHPUT IDENTIFICATION OF BROADLY REACTIVE HLA RESTRICTED T CELL EPITOPES (Converted).